Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 6/20 | 0.59 |
| ▸ | PDCD1 | Q15116 | 12/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.49 |
| ▸ | ATR | Q13535 | 11/20 | 0.49 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487510 | 1.00 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL738140 | 1.00 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL9979426 | 0.91 | PIK3CA (0.55) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL3596412 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2493217 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2493212 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL20798042 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL29026042 | 0.88 | PIK3CA (0.50) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL29026044 | 0.88 | PIK3CA (0.50) | PIK3CAPIK3CDMTORPDCD1CD274 | |
| SCHEMBL2490847 | 0.87 | PIK3CA (0.49) | PIK3CAPIK3CDMTORPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134022-B | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-116134022-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4175948-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022002245-A1 | ATR INHIBITORS AND USES THEREOF | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2022-01-06 | — | — | WO | disclosed |
| CN-102325764-A | Pyrimidine indole derivatives for the treatment of cancer | ASTRAZENECA AB | 2012-01-18 | — | — | CN | disclosed |
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339927-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | PIK3CA 317/4885PIK3CD 347/4885MTOR 943/4885 |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | PIK3CA 1564/4885PIK3CD 2358/4885MTOR 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.